The evolution of hypertension management: The increasing role of triple therapy in clinical practice

Prof. Giuseppe Mancia speaks about the important matter of treatment of high blood pressure. How the hypertension treatment evolve and the increasing role of combination therapy, particularly the triple combination therapy in the clinical practice.

Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-legacy

Prof. Peter Sever speaks about the ASCOT study, what was and is the most influential cardiovascular prevention trial in the last two decades. It is the basis of many hypertension guidelines. He speaks about the past of ASCOT, the recent data and what does it tell us for the future.

ESH-ISH 2021 Late-Breakers Session

Prof. Anna Dominiczak, the chair of the ESH-ISH 2021 Late-Breakers Session speaks about the novelties. Summarized studies: - Effects of blood pressure-lowering on cancer risk: an individual participant data meta-analysis of 300,000 participants https://journals.lww.com/jhypertension/Abstract/2021/04001/EFFECTS_OF_BLOOD_PRESSURE_LOWERING_ON_CANCER_RISK_.17.aspx - Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-legacy https://journals.lww.com/jhypertension/Abstract/2021/04001/LONG_TERM_BENEFITS_OF_BLOOD_PRESSURE_TREATMENT_ON.20.aspx - Self-monitoring of blood pressure in women with pregnancy hypertension: the BUMP2 multicentre randomised controlled trial https://journals.lww.com/jhypertension/Abstract/2021/04001/SELF_MONITORING_OF_BLOOD_PRESSURE_IN_WOMEN_WITH.24.aspx - Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults  https://www.alnylam.com/wp-content/uploads/2021/04/Safety-Pharmacodynamics-and-Blood-Pressure-Effects-of-ALN-AGT-an-RNA-Interference-Therapeutic-Targeting-Angiotensinogen-in-a-Randomized-Single-Ascending-Dose-Study-of-Hypertensive-Adults.pdf

Do we need beta blockers in hypertension?

In the recent years the guidelines changed considerably and the position beta-blockers in a different place that we used previously. Do we need beta-blockers in the treatment of hypertension at all?

Impact of hypertension in the morbidity and mortality in diabetes mellitus: A real-world data

Prof. Josep Redon speaks about how much hypertension increases cardiovascular risk in diabetic patients and what can be the therapeutic consideration when we treat hypertension in the presence of diabetes.

Improving the management of hypertension: acting on key factors

Prof. Neil Poulter speaks about how to improve hypertension awareness and diagnosis.

No(t) a class effect - A crowded class

Prof. Athanasios John Manolis speaks about the big diversity of the beta-blockers and the way how we can chose the best beta-blocker for our preference and for the patients .

The ISH 2020 global hypertension practice guidelines

Professor Alta Schutte updates us briefly on the latest reviews of the new guidelines by The International Society of Hypertension.

Improving the management of hypertension: acting on key factors

Professor Michel Burnier speaks about how to tackle therapeutic inertia. Why it is important to improve the adherence in the treatment of hypertension? What are the medical options to improve the treatment adherence? How to intensify treatment if necessary?

Elevated heart rate in hypertensive patients

Prof. Stefano Masi speaks about why is it important to take heart rate in  consideration for hypertensive patients? What is the evidence that it is important for cardiovascular risk reduction? How can we effectively lower heart rate in hypertensive patients? What drug classes are the most effective?